, Kaleo says it will introduce competitor to Mylan's EpiPen in first half of 2017

Kaleo says it will introduce competitor to Mylan's EpiPen in first half of 2017

Mylan's EpiPen in first half of 2017
Kaleo Inc. stated early Wednesday that its epinephrine vehicle-injector, a competitor to Mylan's MYL, +2.98% EpiPen hypersensitivity treatment that had formerly been recalled, must return to market inside the first half of of 2017. Kaleo, a privately-held agency, stated it had regained the rights from Sanofi SNY, -0.98% which voluntarily recalled the Auvi-Q a year in the past on issues approximately incorrect dose delivery of epinephrine. Kaleo did no longer say what the Auvi-Q's fee could be. Public outrage erupted this summer season over the EpiPen's growing charge, which customers said made the product -- which has an powerful monopoly available on the market and a listing price of over $600 for a two-p.c. -- unaffordable. Mylan stated it'd introduce a $300 authorized well-known product, which the business enterprise stated it plans to make available through the quit of the year. The complete affair has taken a toll on Mylan, with its inventory chickening out 28.five% year up to now, in comparison with a four.nine% upward thrust within the S&P 500 SPX, -zero.38%

Kaleo says it will introduce competitor to Mylan's EpiPen in first half of 2017

Post a Comment

Previous Post Next Post

Contact Form